Verrica Pharmaceuticals Financials
VRCA Stock | USD 0.68 0.03 4.15% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 4.98 | 5.24 |
|
|
The essential information of the day-to-day investment outlook for Verrica Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Verrica Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Verrica Pharmaceuticals.
Net Income |
|
Verrica | Select Account or Indicator |
Please note, the presentation of Verrica Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verrica Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Verrica Pharmaceuticals' management manipulating its earnings.
Verrica Pharmaceuticals Stock Summary
Verrica Pharmaceuticals competes with Inventiva, Edgewise Therapeutics, Vigil Neuroscience, Connect Biopharma, and Acumen Pharmaceuticals. Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. Verrica Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US92511W1080 |
CUSIP | 92511W108 |
Location | Pennsylvania; U.S.A |
Business Address | 44 West Gay |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.verrica.com |
Phone | 484 453 3300 |
Currency | USD - US Dollar |
Verrica Pharmaceuticals Key Financial Ratios
Return On Equity | -20.6 | ||||
Operating Margin | 11.62 % | ||||
Price To Sales | 6.98 X | ||||
Revenue | 5.12 M | ||||
Gross Profit | (13.47 M) |
Verrica Pharmaceuticals Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 74.2M | 80.1M | 44.7M | 81.6M | 93.8M | 62.0M | |
Other Current Liab | 2.9M | 3.3M | 2.4M | 13.9M | 15.9M | 16.7M | |
Net Tangible Assets | 65.0M | 33.0M | 32.6M | 40.0M | 46.0M | 39.3M | |
Net Debt | 24.6M | 27.7M | (32.7M) | (24.0M) | (27.6M) | (29.0M) | |
Retained Earnings | (103.9M) | (139.0M) | (163.5M) | (230.4M) | (207.4M) | (197.0M) | |
Accounts Payable | 348K | 845K | 507K | 2.5M | 2.8M | 3.0M | |
Cash | 10.7M | 15.8M | 34.3M | 69.5M | 80.0M | 84.0M | |
Capital Surpluse | 126.6M | 136.9M | 171.6M | 203.5M | 234.0M | 120.4M | |
Other Current Assets | 4.4M | 7.9M | 8.7M | 2.5M | 2.9M | 3.9M | |
Total Liab | 41.2M | 47.5M | 4.7M | 61.8M | 71.1M | 74.7M | |
Total Current Assets | 65.5M | 74.3M | 39.1M | 77.5M | 89.2M | 57.9M | |
Short Term Debt | 35.7M | 41.9M | 594K | 700K | 805K | 764.8K | |
Net Invested Capital | 68.3M | 74.3M | 40.0M | 62.6M | 72.0M | 64.1M | |
Net Working Capital | 28.2M | 28.3M | 35.7M | 60.5M | 69.6M | 48.9M | |
Other Assets | 1.6M | 295K | 276K | 1.0 | 0.9 | 0.86 |
Verrica Pharmaceuticals Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Net Interest Income | (2.5M) | (4.2M) | (1.7M) | 577K | 519.3K | 545.3K | |
Interest Expense | 3.0M | 4.3M | 2.2M | 4.0M | 4.6M | 4.8M | |
Gross Profit | (229K) | 11.5M | 8.3M | 4.4M | 5.0M | 3.3M | |
Operating Income | (40.2M) | (30.9M) | (21.3M) | (65.8M) | (59.2M) | (56.2M) | |
Ebit | (39.7M) | (30.8M) | (22.3M) | (63.0M) | (56.7M) | (53.9M) | |
Research Development | 15.7M | 15.9M | 12.2M | 20.3M | 23.3M | 13.4M | |
Ebitda | (39.4M) | (30.3M) | (21.6M) | (62.2M) | (56.0M) | (53.2M) | |
Cost Of Revenue | 229K | 472K | 725K | 746K | 857.9K | 900.8K | |
Income Before Tax | (42.7M) | (35.1M) | (24.5M) | (67.0M) | (60.3M) | (57.3M) | |
Net Income | (45.5M) | (38.9M) | (27.7M) | (67.0M) | (60.3M) | (57.3M) | |
Income Tax Expense | 2.8M | 3.8M | 3.2M | 668.1K | 768.3K | 729.9K | |
Interest Income | 521K | 123K | 476K | 2.2M | 2.6M | 2.7M |
Verrica Pharmaceuticals Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Investments | (1.9M) | 86K | 54.5M | 6.6M | 7.6M | 8.0M | |
Change In Cash | 1.4M | 5.1M | 18.5M | 35.3M | 40.6M | 42.6M | |
Free Cash Flow | (31.7M) | (28.5M) | (19.0M) | (38.9M) | (35.0M) | (33.3M) | |
Depreciation | 229K | 472K | 718K | 836K | 961.4K | 1.0M | |
Capital Expenditures | 1.5M | 883K | 302K | 362K | 325.8K | 602.1K | |
Net Income | (42.7M) | (35.1M) | (24.5M) | (67.0M) | (60.3M) | (57.3M) | |
End Period Cash Flow | 10.7M | 15.8M | 34.3M | 69.5M | 80.0M | 84.0M | |
Change To Netincome | 3.3M | 10.6M | 7.5M | 6.8M | 7.8M | 4.8M | |
Other Non Cash Items | 940K | 1.4M | 1.9M | 3.3M | 3.8M | 4.0M |
Verrica Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Verrica Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Verrica Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Verrica Pharmaceuticals competition to find correlations between indicators driving Verrica Pharmaceuticals's intrinsic value. More Info.Verrica Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Verrica Pharmaceuticals' Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Verrica Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Verrica Pharmaceuticals Systematic Risk
Verrica Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Verrica Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Verrica Pharmaceuticals correlated with the market. If Beta is less than 0 Verrica Pharmaceuticals generally moves in the opposite direction as compared to the market. If Verrica Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Verrica Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Verrica Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Verrica Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Verrica Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Verrica Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Verrica Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Verrica Pharmaceuticals February 27, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Verrica Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Verrica Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Verrica Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Verrica Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Verrica Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio | (0.04) | |||
Maximum Drawdown | 23.05 | |||
Value At Risk | (8.57) | |||
Potential Upside | 11.71 |
Complementary Tools for Verrica Stock analysis
When running Verrica Pharmaceuticals' price analysis, check to measure Verrica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verrica Pharmaceuticals is operating at the current time. Most of Verrica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Verrica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verrica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Verrica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Valuation Check real value of public entities based on technical and fundamental data |